Article
Investigating the mechanisms underlying Bortezomib resistance
2023-07-31
Abstract excerpt
Proteasome inhibitors such as Bortezomib, represent an established type of targeted treatment for several types of hematological malignancies, including multiple myeloma, Waldenstrom’s macroglobulinemia and mantle cell lymphoma, based on the cancer cell’s susceptibility upon impairment of the proteasome-ubiquitin system. However, a major problem limiting their efficacy is the emergence of resistance. Their applica...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b6ea6c16-a700-5c30-8c0f-2d4f1d066840
- DOI
- 10.1101/2023.07.29.551081
